Pemetrexed in thoracic cancer

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 7, 2006, Pages 917-928

  Goeminne, Hannelore ^a   van Meerbeeck, Jan P ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Mesorhelioma; Non small cell lung cancer; Pemetrexed

Indexed keywords

CARBOPLATIN; CARCINOGEN; CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EDATREXATE; EPIRUBICIN; FLUOROURACIL; FOLIC ACID; FOLIC ACID ANTAGONIST; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; MITOMYCIN; NAVELBINE; PEMETREXED; PLATINUM DERIVATIVE; RALTITREXED; TRIMETREXATE; VINDESINE;

ADVANCED CANCER; AGE DISTRIBUTION; BONE MARROW TOXICITY; CANCER INCIDENCE; CLINICAL TRIAL; DEVELOPED COUNTRY; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RETENTION; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; HUMAN; INHALATION; LUNG CANCER; MESOTHELIOMA; MUCOSA INFLAMMATION; NEUROPATHY; NEUTROPENIA; NONHUMAN; REVIEW; SEPSIS; THORAX CANCER; TREATMENT OUTCOME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; DRUG THERAPY, COMBINATION; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; THORACIC NEOPLASMS;

EID: 33646562490     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.7.917     Document Type: Review

References (65)

1. PETO J, DECARLI A. LA VECCHIA C et al.: The European mesothelioma epidemic. Br. J. Cancer (1999) 79:666-672.
2. DAMHUIS RA, VAN GELDER T. Malignant mesothelioma in the Rotterdam area, 1987-1989. Eur. J. Cancer (1993) 29A. 1478-1479.
3. CHAILLEUX E, PIOCHE D, CHOPRA S et al.: The epidemiology of malignant pleural mesothelioma in the Nantes-Saint-Nazaire region. Evolution between 1956 and 1992. Rev. Mal. Resp. (1995) 12:353-357.
4. HODGSON JT, MCELVENNY DM, DARNTON AJ, PRICE MJ, PETO J: The expected burden of mesothelioma mortality in Great Britain from 2002-2050. Br. J. Cancer (2005) 92:587-593.
5. CRAIGHEAD JE, ABRAHAM JL, CHURG A et al.: The pathology of asbestos-associated diseases of the lungs and pleural cavities: diagnostic criteria and proposed grading schema. Report of the Pneumoconiosis Committee of the College of American Pathologists and the National Institute for Occupational Safety and Health. Arch. Pathol. Lab. Med. (1982) 106:544-596.
6. SPIRTAS R, CONNELLY RR, TUCKER MA. Survival patterns for malignant mesothelioma: the SEER experience. Int. J. Cancer (1988) 41:525-530.
7. BAAS P VAN MEERBEECK J, GROEN H et al.: Caelyx in malignant mesothelioma: a Phase II EORTC study. Ann. Oncol. (1998) 16:145-152.
8. MATTSON K,GIACCONE G, KIRKPATRICK A et al.: Epirubicin in malignant mesothelioma: a Phase II study of the EORTC-LCCG. J. Clin. Oncol. (1992) 10:824-828.
9. SAHMOUD T, POSTMUS PE, VAN POTTELSBERGHE C et al.: Etoposide in malignant pleural mesothelioma: two Phase II trial of the EORTC Lung Cancer Cooperative Group. Eur. J. Cancer (1997) 33:2211-2215.
10. VAN MEERBEECK J, DEBRUYNE C, VAN ZANDWIJK N et al.: Paclitaxel for malignant pleural mesothelioma: a Phase II study of the EORTC Lung Cancer Cooperative Group. Br. J. Cancer (1996) 74:961-963.
11. VAN BREUKELEN FJ, MATTSON K, GIACCONE G et al.: Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group. Eur. J. Cancer (1991) 27:1627-1629.
12. VAN MEERBEECK JP, BAAS P, DEBRUYNE C et al.: A Phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma. Eur. J. Cancer (2000) 38:779-783.
13. VAN MEERBEECK JP, BAAS P, DEBRUYNE C et al.: A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. Cancer (1999) 85(12):2577-2582.
14. BERGHMANS T, PAESMANS M, LALAMI Y et al.: Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer (2002) 38:111-121.
15. SOLHEIM OP, SAETER G, FINNANGER AM, STENWIG AE: High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A Phase II study. Br. J. Cancer (1992) 65:956-960.
16. GINSBERG RJ, VOKES EE, RABEN A. Cancer of the lung II. Non-small-cell lung cancer. In: Cancer: Principles and Practice of Oncology. VT De Vita (Ed.), Lippincott, Williams and Wilkins, Philadelphia, PA, USA (1997):858-910.
17. DELBALDO C, MICHIELS S, SYZ N, SORIA JC, LE CHEVALIER T, PIGNON JP: Benefits of adding a drug to single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA (2004) 292:470-484.
18. FOSSELLA F, DEVORE R, KERR RN et al.: Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J. Clin. Oncol. (2000) 18:2354-2356.
19. SHEPHERD FA, FOSSELLA FV, LYNCH T, ARMAND JP, RIGAS JR, KRIS MG: Docetaxel (taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two Phase III trials. Semin. Oncol. (2001) 28(1 Suppl. 2):4-9.
20. LYNN B, BAILEY, JESSE F, GREGORY JF III: Folate metabolism and requirements. J. Nutr. (1999) 4:79-82.
21. WAGNER C: Biochemical role of folate in cellular metabolism. In: Folate in Health and Disease. LB Baily (Ed.), Marcel Dekker, New York, NY, USA (1995):23-42.
22. SHIH C, CHEN VJ, GOSSETT LS et al.: LY231514, a pyrrolo(2,3-d)pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. (1997) 57:1116-2011.
23. SCHULTZ RM, PATEL VF, WORZALLA JF, SHIH CA. Role of thymidylate synthase in the antitumour activity of the multitargeted antifolate, LY231514. Anticancer Res. (1999) 19(1A):437-443.
24. GREM JL: Fluoritaned pyrimides. In: Cancer Chemotherapy: Principles and Practice. BA Chabner, JM Collins (Eds), Lippincott, Philadelphia, PA, USA (1990):180-224.
25. ZHAO R, BABANI S, GAO F, LIU L, GOLDMAN ID: The mechanism of transport of the multitargeted antifolate. MTA-LY231514, and its cross-resistance pattern in cell with impaired transport of methotrexate. Clin. Res. (2000) 6:3687-3695.
26. SHIH C, MENDELSOHN LG, CHEN VJ, SCHULZ RM: Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv. Enzyme Regul. (1998) 38:135-152.
27. ADJEI AA: Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev. Anticancer. Ther. (2003) 3(2):145-156.
28. HAZARIKA M, WHITE R, BOOTH BP et al.: Pemetrexed in malignant pleural mesothelioma. Clin. Cancer Res. (2005) 11:982-999.
29. HANAUSKE AR, CHEN V, PAOLETTI P, NIYIKIZA C: Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumours. Onologist (2001) 6:145-156.
30. THÖDTMANN R, DEPENBROCK H, DUMEZ H et al.: Clinical and pharmacokinetic Phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J. Clin. Oncol. (1999) 17:3009-3301.
31. HUGHES A, CALVERT P, AZZABI A et al.: Phase I clinical and pharmakinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma J. Clin. Oncol. (2002) 20:3533-3544.
32. SCAGLIOTTI GV, SHIN DM, KINDLER HL et al.: Phase II study of pemetrexed with and without folic acid and vitamine B12 as front-line therapy in malignant pleural mesothelioma. J. Clin. Oncol. (2003) 21:1556-1561.
33. KATAZYNA P, GAREY JS: Pemetrexed therapy for malignant pleural mesothelioma. Ann. Pharmacother. (2005) 39:678-683.
34. SOTO PARRA H, ZUCALI P, FAVARETTO A et al.: A Phase II study of pemetrexed and carboplatin as front-line chemotherapy in patients with malignant pleural mesothelioma (MPM) P-428. Lung Cancer (2005) 2:S229.
35. JANNE P, SIMON G, LANGER C et al.: An update of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (pts) with malignant pleural mesothelioma (MPM): a Phase II clinical trial. Lung Cancer (2005) 49:S281.
36. VOGELZANG NJ, RUSTHOVEN JJ, SYMANOWSKI J et al.: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. (2003) 21:2636-2644.
37. VOGELZANG N, SYMANOWSKI J, RUSTHOVEN J et al.: Long-term survival update from the randomized Phase III study of pemetrexed plus cisplatin versus cisplatin in patients with malignant pleural mesothelioma (MPM). Lung Cancer (2005) 49(2):S231.
38. PAOLETTI P, PISTOLESI M, RUSTHOVEN JJ et al.: Correlation of pulmonary function tests with best tumour response status: results from the Phase III study of pemetrexed + cisplatin versus cisplatin in malignant pleural mesothelioma. Proc. Am. Soc. Clin. Oncol. (2003) 22:659. Abstr. 2651.
39. HOLLEN PJ, GRALLA JP, LIEPA AM, SYMANOWSKI JT, RUSTHOVEN J: Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma. Cancer (2004) 101:587-595.
40. SYMANOWSKI J, RUSTHOVEN J, VOGELZANG NJ: Updated multiple regression analysis of prognostic variables for survival in malignant pleural mesothelioma (MPM): observations from a Phase III study of pemetrexed plus cisplatin versus cisplatin and evolution of the regression model. Lung Cancer (2005) 49(2):S230.
41. CLARKE SJ, ABRATT R, GOEDHALS L, BOYER MJ, MILLWARD, ACKLAND SP: Phase II trial of pemetrexed disodium in chemotherapy-naïve patients with advanced non-small-cell lung cancer. Ann. Oncol. (2001) 13:737-741.
42. RUSTHOVEN J, EISENHAUER E, BUTTS C et al.: Multitargeted antifolate LY1514 as first line chemotherapy for patients with advanced non-small-cell lung cancer: a Phase II study. J. Clin. Oncol. (1999) 17:1194-1199.
43. SHEPHERD FA, DANCEY J, ARNOLD A et al.: Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced non-small-cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer (2001) 92:595-600.
44. MANEGOLD C, GATZEMEIER U, VON PAWEL J et al.: Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, Alimta) and cisplatin: a multicenter Phase II trial. Ann. Oncol. (2000) 11:435-440.
45. KOSHY S, HERBST RS, OBASAJU CK et al.: A Phase II trial of pemetrexed (P) plus carboplatin (C) in patients with advanced non-small-cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (2004) 23:631A.
46. ADJEI AA. Preclinical and clinical studies studies with combinations of pemetrexed and gemcitabine. Semin. Oncol. (2002) 29(6 Suppl. 18):30-34.
47. MONNERAT C, LECHEVALIER T, KELLY K et al.: Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small lung cancer. Clin. Cancer Res. (2004) 10:5439-5446.
48. SARITA DUBEY, SCHILLER JH: Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab. Oncologist (2005) 10:282-291.
49. SCAGLIOTTI GV, KORTSIK C, DARK GG et al.: Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized Phase II trial. Clin. Cancer Res. (2005) 11:690-696.
50. POSTMUS P, MATTSON K, VON PAWEL J et al.: Phase II trial of MTA (LY231514) in patients (PTS) with non-small-cell lung cancer (NSLC) who relapsed after previous platinum or not-platinum chemotherapy. Eur. J. Cancer (1999) 35:249.
51. ADJEI AA: Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin. Cancer Res. (2004) 10:4276s-4280s.
52. HANNA N, SHEPHERD FA, FOSSELLA FV et al.: Randomised Phase III trial of pemetrexed versus docetaxel (Taxotere) in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. (2004) 22:1589-1597.
53. O'BYRNE K, BONOMI P, PAZ-ARES L, O'BRIEN M, LANGER C, OLDHAM F: Paclitaxel poliglumex versus docetaxel (Taxotere) for the second-line treatment on non-small-cell lung cancer (NSCLC): the STELLAR 2 Phase III study. Eur. J. Cancer (2005) 3:414, PS13.
54. SHEPHERD FA, PEREIRA JR, CIULEANU T et al.: Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med (2005) 353:133-144.
55. SHEPHERD FA. Second-line chemotherapy for non-small cell lung cancer. Expert Rev. Anticancer Ther. (2003) 4:435-442.
56. VAN MEERBEECK J, GAAFAR R, MANEGOLD C et al.: A randomized Phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the EORTC Lung Cancer Group and the NCIC. J. Clin. Oncol. (2005) 23:6881.
57. BYRNE MJ, DAVIDSON JA, MUSK AW et al.: Cisplatin and gemcitabine treatment for malignant mesothelioma: a Phase II study. J. Clin. Oncol. (1999) 17(1):25-30.
58. BERGHMANS T, LAFITTE JJ, PAESMANS M et al.: A Phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma. Lung Cancer (2005) 50:75-82.
59. CHAHINIAN AP, ANTMAN K, CORSONN JM et al.: Randomised Phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J. Clin. Oncol (1993) 11:1559-1565.
60. POUW E, VAN DEN BOGAERT D, VAN WIJHE G, VERNHOUT R, SURMONT V, VAN KLAVEREN R: Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. Lung Cancer (2005) 49:S29.
61. KRUG L, PASS H, RUSCH V et al.: A multicenter Phase II trial of neo-adjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy (EPP) and radiation (RT) for malignant pleural mesothelioma (MPM). Lung Cancer (2005) 49:S223.
62. WEDER W, KESTENHOLZ P, TAVERNA C et al.: Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J. Clin. Oncol. (2004) 22:3451-3457.
63. BISCHOF M, WEBER KJ, BLATTER J, WANNENMACHER M, LATZ D: Interaction of pemetrexed disodium (Alimta, multitargeted antifolate) and irradiation in vitro. Int J. Radiat. Oncol. Biol. Phys. (2002) 52:1381-1388.
64. TEICHER BA, ALVAREZ E, LIU P et al.: MTA (LY231514) in combination treatment regimens using human tumour xenographts and the EMT-6 murine mammary carcinoma. Semin. Oncol. (1999) 26(2 Suppl. 6):55-62.
65. SEIWERT T, CONNELL P, MAUER M et al.: Pemetrexed-based concurrent chemoradiotherapy (CRT) for locally advanced or metastatic non-small-cell lung or oesophageal cancer. a Phase I dose-escalating study. Lung Cancer (2005) 49:S80.